Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia

Mayo Clinic Proceedings

Volumn 76, Issue 6, 2001, Pages 619-631

  Napoli, Claudio ^a,b,c   Lerman, Lilach O ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c MAYO CLINIC   (United States)

Author keywords

CHD = coronary heart disease; eNOS = endothelial nitric oxide synthase; HMG CoA = 3 hydroxy 3 methylglutaryl coenzyme A; IL = interleukin; iNOS = inducible nitric oxide synthase; LAD = left anterior descending; LDL = low density lipoprotein; NADPH = nicotine adenine dinucleotide phosphate; NF B = nuclear factor B; NO = nitric oxide; NOS = nitric oxide synthase; ROS = reactive oxygen species

Indexed keywords

CYTOKINE; GROWTH FACTOR; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE RELEASE; GENETIC DISORDER; HYPERCHOLESTEROLEMIA; INFLAMMATION; METABOLIC DISORDER; PREGNANCY; REVIEW; RISK FACTOR; SHEAR STRESS; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

EID: 0034969485     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.6.619     Document Type: Review

References (183)

1. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholestérol concentration and mortality: the Whitehall Study. JAMA. 1992;267:70-76.
2. Brown WV. Hypercholesterolemia in the United States: how far have we come? Am J Med. 1997; 102(2A):3-6.
3. Grundy SM. Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease. Am J Med. 1997; 102(2A): 15-22.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
5. Yamada M, Wong FL, Kodama K, Sasaki H, Shimaoka K, Yamakido M. Longitudinal trends in total serum cholesterol levels in a Japanese cohort, 1958-1986. J Clin Epidemiol. 1997;50:425-434.
6. Zhou B, Rao X, Dennis BH, et al, PRC-USA Cardiovascular and Cardiopulmonary Research Group. The relationship between dietary factors and serum lipids in Chinese urban and rural populations of Beijing and Guangzhou. Int J Epidemiol. 1995;24:528534.
7. Woo KS, Chook P, Raitakari OT, McQuillan B, Feng JZ, Celermajer DS. Westernization of Chinese adults and increased subclinical atherosclerosis. Arterioscler Thromb Vase Biol. 1999; 19:2487-2493.
8. Gniwotta C, Morrow JD, Roberts LJ II, Kühn H. Prostaglandin F,like compounds, F,-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterioscler Thromb Vase Biol. 1997;17:3236-3241.
9. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993; 87:1781-1791.
10. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu Rev Med. 1993;44:365-376.
11. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101 : 948-954.
12. Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol. 1997; 80(9A):11I-16I.
13. Britten M, Schachinger V. The role of endothelial function for ischémie manifestations of coronary atherosclerosis [in German]. Herz. 1998;23:97-105.
14. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol. 1995;75:75B-81B.
15. Lerman LO, Nath KA, Rodriguez-Porcel M, et al. Increased oxidative stress in experimental renovascular hypertension. Hypertension. 2001;37(2, pt 2, suppl S):541-546.
16. Rodriguez-Porcel M, Krier JD, Lerman A, et al. Combination of hypercholesterolemia and hypertension augments renal function abnormalities. Hypertension. 2001;37(2, pt 2, suppl S):774780.
17. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N EnglJ Med. 1986;315:1046-1051.
18. Lerman A, Burnett JC Jr. Intact and altered endothelium in regulation of vasomotion. Circulation. 1992;86(suppl 3):III-12-III-19.
19. Cooper A, Heagerty AM. Endothelial dysfunction in human intramyocardial small arteries in atherosclerosis and hypercholesterolemia. AmJPhysiol. 1998;275(4, pt 2):H1482-H1488.
20. Hamasaki S, Higano ST, Suwaidi JA, et al. Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries. Arterioscler Thromb Vase Biol. 2000;20:737-743.
21. Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol. 1997;79(5A): 24-28.
22. Luscher TF, Tanner FC, Noll G. Lipids and endothelial function: effects of lipid-lowering and other therapeutic interventions. Curr OpinLipidol. 1996;7:234-240.
23. Vogel RA, Corretti MC, Gellman J. Cholesterol, cholesterol lowering, and endothelial function. Prog Cardiovasc Dis. 1998;41: 117-136.
24. de Nigris F, Franconi F, Maida I, Palumbo G, Anania V, Napoli C. Modulation by a- and y-tocopherol and oxidized low-density lipoprotein of apoptotic signaling in human coronary smooth muscle cells. Biochem Pharmacol. 2000;59:1477-1487.
25. de Nigris F, Youssef T, Ciafré S, et al. Evidence for oxidative activation of c-Myc-dependent nuclear signaling in human coronary smooth muscle cells and in early lesions of Watanabe heritable hyperlipidemic rabbits: protective effects of vitamin E. Circulation. 2000;102:2111-2117.
26. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol. 1999;34:879-886.
27. Mercurio F, Manning AM. Multiple signals converging on NFkappaB. Curr Opin Cell Biol. 1999;11:226-232.
28. Napoli C, Quehenberger O, de Nigris F, Abete P, Glass CK, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 2000; 14:1996-2007.
29. Wilson SH, Caplice NM, Simari RD, Holmes DR Jr, Carlson PJ, Lerman A. Activated nuclear factor-KB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis. 2000:148:23-30.
30. de Nigris F, Lerman LO, Rodriguez-Porcel M, De Montis MP, Lerman A, Napoli C. c-Myc activation in early coronary lesions in experimental hypercholesterolemia. Biochem Biophvs Res Commun. 2001 ;281:945-950.
31. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999; 43:562-571.
32. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vase Biol. 2000:20:21752183.
33. Ferdinandy P, Schulz R. Peroxynitrite: toxic or protective in the heart? Cire Res. 2001;88:E12-E13.
34. Hennig B, Chow CK. Lipid peroxidation and endothelial cell injury: implications in atherosclerosis. Free Radie Biol Med. 1988;4:99-106.
35. Ross R. Atherosclerosis-an inflammatory disease. N Engt J Med. 1999;340:115-126.
36. Stemerman MB. Lipoprotein effects on the vessel wall [editorial]. Circ Res. 2000;86:715-716.
37. Pritchard KA Jr, Groszek L, Smalley DM, et al. Native lowdensity lipoprotein increases endothelial cell nitric oxide synthase generation of Superoxide anion. Circ Res. 1995;77:510-518.
38. Hein TW, Kuo L. LDLs impair vasomotor function of the coronary microcirculation: role of Superoxide anions. Circ Res. 1998; 83:404-414.
39. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86: 494-501.
40. Cardillo C, Kilcoyne CM, Cannon RO III, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 1997;30(1, pt l):57-63.
41. Wolin MS. Reactive oxygen species and vascular signal transduction mechanisms. Microcirculation. 1996;3:1-17.
42. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radie Biol Med. 1996;20:707-727.
43. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999;85:753-766.
44. Hoshida S, Yamashita N, Kuzuya T, Hori M. Differential effects of long-term renin-angiotensin system blockade on limitation of infarct size in cholesterol-fed rabbits. Atherosclerosis. 2000; 149: 287-294.
45. Rajagopalan S, Kurz S, Münzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular Superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916-1923.
46. De Keulenaer GW, Chappell DC, Ishizaka N, Nerem RM, Alexander RW, Griendling KK. Oscillatory and steady laminar shear stress differentially affect human endothelial redox state: role of a superoxide-producing NADH oxidase. Circ Res. 1998; 82:1094-1101.
47. White CR, Darley-Usmar V, Berrington WR, et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sei USA. 1996;93: 8745-8749.
48. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease [editorial]. Circulation. 1997;96:3264-3265.
49. Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC. Impaired Superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vase Biol. 2000;20:1529-1535.
50. Alexander RW. Atherosclerosis as disease of redox-sensitive genes. Trans Am Clin Climatol Assoc. 1998;109:129-145.
51. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vase Biol. 1997; 17:1859-1867.
52. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice [editorial]. Circulation. 1999; 100: 1148-1150.
53. Chen X-L, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res. 1998;83:952-959.
54. Ishizaka N, De Leon H, Laursen JB, et al. Angiotensin II-induced hypertension increases heme oxygenase-1 expression in rat aorta. Circulation. 1997;96:1923-1929.
55. El-Swefy S, Schaefer EJ, Seman LJ, et al. The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters. Atherosclerosis. 2000; 149:277-286.
56. a56. Pieper GM, Riaz-ul-Haq. Activation of nuclear factor-KB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J Cardiovasc Pharmacol. 1997;30:528-532.
57. Kakoki M, Hirata Y, Hayakawa H, et al. Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation. 1999;99:1242-1248.
58. Posch K, Simecek S, Wascher TC, et al. Glycated low-density lipoprotein attenuates shear stress-induced nitric oxide synthesis by inhibition of shear stress-activated L-arginine uptake in endothelial cells. Diabetes. 1999;48:1331-1337.
59. Pryor WA. Vitamin E and heart disease: basic science to clinical intervention trials. Free Radie Biol Med. 2000;28:141-164.
60. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res. 1998;39:8-33.
61. Fuster V, Poon M, Willerson JT. Learning from the transgenic mouse: endothelium, adhesive molecules, and neointimal formation [editorial]. Circulation. 1998;97:16-18.
62. Palinski W, Napoli C, Reaven PD. Mouse models of atherosclerosis. In: Simon DI, Rogers C, eds. Vascular Disease and Injury: Preclinical Research. Totowa, NJ: Humana Press; 2001:149-174. Contemporary Cardiology series.
63. Shimokawa H, Vanhoutte PM. Hypercholesterolemia causes generalized impairment of endothelium-dependent relaxation to aggregating platelets in porcine arteries. J Am Coll Cardiol. 1989; 13:1402-1408.
64. Lerman A, Webster MWI, Chesebro JH, et al. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993;88:2923-2928.
65. Knowles JW, Maeda N. Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb Vase Biol. 2000;20:2336-2345.
66. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI. The NF-KB signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. ProcNatl AcadSei USA. 2000;97:9052-9057.
67. Bloor CM, White FC, Roth DM. The pig as a model of myocardial ischemia and gradual coronary artery occlusion. In: Swindle MM, ed. Swine as Models in Biomédical Research. Ames: Iowa State University Press; 1992:163-175.
68. Mathew V, Cannan CR, Miller VM, et al. Enhanced endothelinmediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation. 1997;96:1930-1936.
69. Best PJM, Lerman LO, Romero JC, Richardson D, Holmes DR Jr, Lerman A. Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro. Arterioscler Thromb Vase Biol. 1999; 19: 2769-2775.
70. Wilson SH, Best PJM, Lerman LO, Holmes DR Jr, Richardson DM, Lerman A. Enhanced coronary vasoconstriction to oxidative stress product, 8-epi-prostaglandinF2a, in experimental hypercholesterolemia. Cardiovasc Res. 1999;44:601-607.
71. Hasdai D, Mathew V, Schwartz RS, et al. Enhanced endothelin-Breceptor-mediated vasoconstriction of small porcine coronary arteries in diet-induced hypercholesterolemia. Arterioscler Thromb Vase Biol. 1997; 17:2737-2743.
72. Best PJM, McKenna CJ, Hasdai D, Holmes DR Jr, Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation. 1999;99:1747-1752.
73. Möhlenkamp S, Lerman LO, Lerman A, et al. Minimally invasive evaluation of coronary microvascular function by electron beam computed tomography. Circulation. 2000; 102:2411-2416.
74. Rodriguez-Porcel M, Lerman A, Ritman EL, Wilson SH, Best PJM, Lerman LO. Altered myocardial microvascular 3D architecture in experimental hypercholesterolemia. Circulation. 2000; 102:2028-2030.
75. Rodriguez-Porcel M, Lerman A, Best PJM, Krier JD, Napoli C, Lerman LO. Hypercholesterolemia impairs myocardial perfusion and permeability: role of oxidative stress and endogenous scavenging activity. J Am Coll Cardiol. 2001 ;37:608-615.
76. Schachinger V. Zeiher AM. Alterations of coronary blood flow and myocardial perfusion in hypercholesterolaemia. Heart. 1996; 76:295-298.
77. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991:83:391-401.
78. Hasdai D, Gibbons RJ, Holmes DR Jr, Higano ST, Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation. 1997:96:3390-3395.
79. Hasdai D, Holmes DR Jr, Higano ST, Burnett JC Jr, Lerman A. Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. Mayo Clin Proc. 1998;73:1133-1140.
80. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem. 1997:272:20963-20966.
81. Tribble DL. Lipoprotein oxidation in dyslipidemia: insights into general mechanisms affecting lipoprotein oxidative behavior. Curr Opin Lipidol. 1995;6:196-208.
82. Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997:386:73-77.
83. Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized lowdensity lipoprotein. Circulation. 1999:100:899-902.
84. Murase T, Kume N, Korenaga R, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. CircRes. 1998:83:328-333.
85. Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. Enhanced expression of endothelial oxidized low-density lipoprotein receptor (LOX-1 ) in hypertensive rats. Biochem Biophvs Res Commun. 1997:237:496-498.
86. Chen M, Kakutani M, Minami M, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vase Biol. 2000;20:1107-1115.
87. Kita T. LOX-1, a possible clue to the missing link between hypertension and atherogenesis. Circ Res. 1999;84:1113-1115.
88. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1 ) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vase Biol. 2000:20:1116-1122.
89. Chait A. Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. AmJ Med. 1993:94:350-356.
90. Napoli C, Ambrosio G, Scarpato N, et al. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J. 1997: 133:585-595.
91. Napoli C, Postiglione A, Triggiani M, et al. Oxidative structural modifications of low density lipoprotein in homozygous familial hypercholesterolemia. Atherosclerosis. 1995:118:259-273.
92. Reaven PD, Napoli C, Merat S, Witztum JL. Lipoprotein modification and atherosclerosis in aging. Exp Gerontol. 1999:34:527537.
93. Cox DA, Cohen ML. Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Pharmacol Rev. 1996;48:3-19.
94. Flavahan NA. Lysophosphatidylcholine modifies G protein-dependent signaling in porcine endothelial cells. Am J Phvsiol. 1993:264(3, pt 2):H722-H727.
95. Järvisalo MJ, Toikka JO, Vasankari T, et al. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis. 1999:147:237-242.
96. Shepherd J. Cobbe SM, Ford I, et al, West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995:333:1301-1307.
97. Luscher TF, Tanner FC, Dohi Y. Age, hypertension and hypercholesterolaemia alter endothelium-dependent vascular regulation. Pharmacol Toxicol. 1992:70(6, pt 2):S32-S39.
98. John S. Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens. 2000; 18:363-374.
99. Vasquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. P roc Natl Acad Sei USA. 1998;95:9220-9225.
100. Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radie Res. 1999:31:577-596.
101. Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res. 2000:86:347-354.
102. Peterson TE, Poppa V, Ueba H, Wu A, Van C, Berk BC. Opposing effects of reactive oxygen species and cholesterol on endothelial nitric oxide synthase and endothelial cell caveolae. Circ Res. 1999:85:29-37.
103. Arnal JF. Dinh-Xuan AT, Pueyo M, Darblade B, Rami J. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sei. 1999:55:1078-1087.
104. Bucci M. Gratton JP, Rudic RD, et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med. 2000:6:1362-1367.
105. Feron O. Dessy C, Desager J-P, Balligand J-L. Hydroxymethylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001:103:113-118.
106. Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterologv. 1999:117: 1222-1228.
107. Heinzel B, John M, Klatt P, Bohme E, Mayer B. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J. 1992;281(pt 3):627-630.
108. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000:87:840-844.
109. Detmers PA, Hernandez M, Mudgett J, et al. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol. 2000; 165:34303435.
110. Behr-Roussel D, Rupin A, Sansilvestri-Morel P, Fabiani JN, Verbeuren TJ. Histochemical evidence for inducible nitric oxide synthase in advanced but non-ruptured human atherosclerotic carotid arteries. Histochem J. 2000;32:41-51.
111. Luoma JS, Strâlin P, Marklund SL, Hiltunen TP, Särkioja T, YläHerttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscier Thromb Vase Biol. 1998; 18:157-167.
112. Hickey MJ. Role of inducible nitric oxide synthase in the regulation of leucocyte recruitment. Clin Sei (Colch). 2001:100:1-12.
113. Behr-Roussel D. Rupin A, Simonet S, et al. Effect of chronic treatment with the inducible nitric oxide synthase inhibitor Wiminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hypercholesterolemic rabbits. Circulation. 2000:102:1033-1038.
114. De Meyer GR, Kockx MM, Cromheeke KM, Seye CI, Herman AG, Bull H. Periadventitial inducible nitric oxide synthase expression and intimai thickening. Arterioscier Thromb Vase Biol. 2000:20:1896-1902.
115. Fukumoto Y, Shimokawa H, Kozai T, et al. Vasculoprotective role of inducible nitric oxide synthase at inflammatory coronary lesions induced by chronic treatment with interleukin-1β in pigs in vivo. Circulation. 1997;96:3104-3111.
116. Schwartz D, Mendonca M, Schwartz I, et al. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest. 1997; 100:439-448.
117. Napoli C, Ignarro LJ. Nitric oxide and atherosclerosis. Nitric Oxide. 2001;5:88-97.
118. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489-509.
119. Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year 2000: a historical look to the future. Ann N YAcad Sei. 2000; 899:136-147.
120. Wolin MS. Interactions of oxidants with vascular signaling systems. Arteriosder Thromb Vase Biol. 2000;20:1430-1442.
121. Bloodsworth A, O'Donnell VB, Freeman BA. Nitric oxide regulation of free radical- and enzyme-mediated lipid and lipoprotein oxidation. Arteriosder Thromb Vase Biol. 2000;20:1707-1715.
122. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med. 1998;105(1A):32S-39S.
123. Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation. 1991 ;84:1984-1992.
124. Tousoulis D, Tentolouris C, Crake T, Toutouzas P, Davies G. Basal and flow-mediated nitric oxide production by atheromatous coronary arteries. J Am Coll Cardiol. 1997;29:1256-1262.
125. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
126. Feldstein A, Krier JD, Sarafov MH, et al. In vivo renal vascular and tubular function in experimental hypercholesterolemia. Hypertension. 1999;34(4, pt 2):859-864.
127. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol. 1994;23:844-850.
128. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl AcadSdUSA. 1999;96:11041-11048.
129. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
130. Sacks FM, Pfeffer MA, Moye LA, et al, Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
131. Farmer JA, Gotto AM. Choosing the right lipid-regulating agent: a guide to selection. Drugs. 1996;52:649-661.
132. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol. 1999;10:561-574.
133. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207-213.
134. Ansell B J, Watson KE, Fogelman AM. An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines: National Cholesterol Education Program. JAMA. 1999;282:2051-2057.
135. Griffin KL, Laughlin MH, Parker JL. Exercise training improves endothelium-mediated vasorelaxation after chronic coronary occlusion. J Appl Physiol. 1999;87:1948-1956.
136. Rush JWE, Laughlin MH, Woodman CR, Price EM. SOD-1 expression in pig coronary arterioles is increased by exercise training. Am J Physiol Heart Circ Physiol. 2000;279:H2068H2076.
137. Koller-Strametz J, Matulla B, Wolzt M, et al. Role of nitric oxide in exercise-induced vasodilation in man. Life Sd. 1998;62:10351042.
138. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimai accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:26802690.
139. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999;354:1234-1241.
140. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Gene expression in macrophage-rich human atherosclerotic lesions: 15lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest. 1991 ;87:1146-1152.
141. Fuller CJ, Grundy SM, Norkus EP, Jialal I. Effect of ascorbate supplementation on low density lipoprotein oxidation in smokers. Atherosclerosis. 1996;119:139-150.
142. Freyschuss A, Xiu RJ, Zhang J, et al. Vitamin C reduces cholesterol-induced microcirculatory changes in rabbits. Arterioscler Thromb Vase Biol. 1997; 17:1178-1184.
143. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
144. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P, Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154-160.
145. Carr AC, Zhu BZ, Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res. 2000;87:349-354.
146. Porkkala-Sarataho E, Salonen JT, Nyyssonen K, et al. Longterm effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2'-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. Arterioscler Thromb Vase Biol. 2000;20:20872093.
147. Khajehdehi P. Effect of vitamins on the lipid profile of patients on regular hemodialysis. ScandJ Urol Nephrol. 2000;34:62-66.
148. Wilson SH, Simari RD, Best PJM, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vase Biol. 2001 ;21 : 122-128.
149. Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998;31:684-691.
150. Weiss RH, Ramirez A, Joo A. Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kipl and PI3 kinase. J Am Soc Nephrol. 1999;10:1880-1890.
151. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
152. Simons M. Molecular multitasking: statins lead to more arteries, less plaque. Nat Med. 2000;6:965-966.
153. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-lbeta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferatoractivated receptor alpha (PPARalpha) in primary endothelial cells. Life Sei. 2000;67:863-876.
154. Neunteufl T, Kostner K, Katzenschlager R, Zehetgruber M, Maurer G, Weidinger F. Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol. 1998; 32:711-716.
155. Schettler V, Methe H, Staschinsky D, Schuff-Werner P, Muller GA, Wieland E. Review: the oxidant/antioxidant balance during regular low density lipoprotein apheresis. Ther Apher. 1999; 3:219-226.
156. van Boven AJ, Jukema JW, Paoletti R. Endothelial dysfunction and dyslipidemia: possible effects of lipid lowering and lipid modifying therapy. Pharmacol Res. 1994;29:261-272.
157. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234.
158. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endotheliurn-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90: 1248-1253.
159. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 1991 ;338:15461550.
160. Tousoulis D, Davies G, Tentolouris C, Crake T, Toutouzas P. Coronary stenosis dilatation induced by L-arginine [letter]. Lancet. 1997;349:1812-1813.
161. Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation. 1998;97: 2123-2128.
162. Blum A, Porat R, Rosenschein U, et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. Am J Cardiol. 1999;83:1488-1490, A8.
163. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth: findings from the PDAY Study. A rterioscler Thromb. 1993 ; 13:1291 -1298.
164. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA, Bogalusa Heart Study. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338:1650-1656.
165. Napoli C, Palinski W. Maternal hypercholesterolemia during pregnancy influences the later development of atherosclerosis: clinical and pathogenic implications. Eur Heart J. 2001 ;22:4-9.
166. Palinski W, Napoli C. Pathophysiological events during pregnancy influence the development of atherosclerosis in humans. Trends Cardiovasc Med. 1999;9:205-214.
167. Napoli C, Witztum JL, de Nigris F, Palumbo G, D'Armiento FP, Palinski W. Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Circulation. 1999;99:2003-2010.
168. Napoli C, Paterne R, Faraci FM, Taguchi H, Postiglione A, Heistad DD. Mildly oxidized low-density lipoprotein impairs responses of carotid but not basilar artery in rabbits. Stroke. 1997; 28:2266-2271.
169. Napoli C, Witztum JL, Calara F, de Nigris F, Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normo-
170. cholesterolemic rabbits, which is inhibited by antioxidant or lipidlowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Ci re Res. 2000;87: 946-952.
171. Cleeman JI, Grundy SM. National Cholesterol Education Program recommendations for cholesterol testing in young adults: a science-based approach. Circulation. 1997:95:1646-1650.
172. American Academy of Pediatrics. National Cholesterol Education Program: report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89(3, pt 2):525584.
173. Duplaga B A. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors. Ann Pharmacother. 1999;33: 1224-1227.
174. Hozumi T, Yoshida K, Ogata Y, et al. Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography. Circulation. 1998;97:1557-1562.
175. Isaaz K, da Costa A, de Pasquale JP, Cerisier A, Lamaud M. Use of the continuity equation for transesophageal Doppler assessment of severity of proximal left coronary artery stenosis: a quantitative coronary angiography validation study. J Am Coll Cardiol. 1998;32:42-48.
176. Hundley WG, Hamilton ÇA, Clarke CD, et al. Visualization and functional assessment of proximal and middle left anterior descending coronary stenoses in humans with magnetic resonance imaging. Circulation. 1999:99:3248-3254.
177. Caiati C, Montaldo C, Zedda N, et al. Validation of a new noninvasive method (contrast-enhanced transthoracic second harmonic echo Doppler) for the evaluation of coronary flow reserve: comparison with intracoronary Doppler flow wire. J Am Coll Cardiol. 1999;34:1193-1200.
178. Budoff MJ, Georgiou D, Brody A, et al. Ultrafast computed tomography as a diagnostic modality in the detection of coronary artery disease: amulticenterstudy. Circulation. 1996;93:898-904.
179. Guerci AD, Spadaro LA, Popma JJ, et al. Relation of coronary calcium score by electron beam computed tomography to artériographie findings in asymptomatic and symptomatic adults. Am J Cardiol. 1997:79:128-133.
180. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation. 1995;92:2157-2162.
181. Hubel CA. Dyslipidemia, iron, and oxidative stress in preeclampsia: assessment of maternal and feto-placental interactions. Semin Reprod Endocrinol. 1998; 16:75-92.
182. Cockell AP, Poston L. Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension. 1997;30(2, pt 1):247-251.
183. Chappell LC, Seed PT, Briley AL, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet. 1999;354:810-816.